<![CDATA[ Strategy - Aromics]]> <![CDATA[ Strategy - Aromics]]> http://aromics.es/rss/en/products/strategy <![CDATA[]]> AROMICS is convinced that the future of novel drugs and the management of human diseases lies in the development of rationale-driven drugs that are effective, have minimal side effects and improve the patient’s quality of life.

We follow three main approaches:

  • Predicting and understanding the biological effects of the drug on disease progression.
  • Predicting and understanding the mechanisms of action for drug-induced toxicity.
  • Identifying key molecular biomarkers that must be monitored to ensure success of clinical trials or eliminate possible failures early, during preclinical and clinical development.

            Array    protein

We strongly believe that multi-omic data coupled with other relevant data such as pharmacokinetic, phenotypic, physiological, individual genetic variability and clinical measurements represent an important first step towards gaining biological insights into:

  • How drugs work, giving them added value, reducing attrition rates and advancing  through the clinic.
  • Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and  monitor drug response.

Through our own discovery efforts, as well as in-licensing and collaboration research programs, AROMICS is building a portfolio of highly innovative projects in diagnostic and therapeutic areas at various stages of development, from early discovery to proof-of-concept phases. A strong intellectual property portfolio supports our diverse product pipeline.     

]]>